PCLO Stock Overview Together with its subsidiary, engages in cultivating, processing, and supplying medicinal-grade cannabis extracts in Canada. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
PharmaCielo Ltd. Competitors Price History & Performance
Summary of share price highs, lows and changes for PharmaCielo Historical stock prices Current Share Price CA$0.08 52 Week High CA$0.29 52 Week Low CA$0.065 Beta 2.28 1 Month Change -11.11% 3 Month Change -11.11% 1 Year Change -55.56% 3 Year Change -92.79% 5 Year Change -96.68% Change since IPO -98.63%
Recent News & Updates
Third quarter 2024 earnings released: CA$0.016 loss per share (vs CA$0.017 loss in 3Q 2023) Dec 01
New major risk - Market cap size Nov 07
Second quarter 2024 earnings released: CA$0.015 loss per share (vs CA$0.023 loss in 2Q 2023) Aug 18 PharmaCielo Ltd. announced that it expects to receive CAD 2 million in funding Apr 11
PharmaCielo Ltd. announced that it expects to receive CAD 2 million in funding Apr 10
PharmaCielo Ltd., Annual General Meeting, Feb 20, 2024 Dec 28 See more updates
Third quarter 2024 earnings released: CA$0.016 loss per share (vs CA$0.017 loss in 3Q 2023) Dec 01
New major risk - Market cap size Nov 07
Second quarter 2024 earnings released: CA$0.015 loss per share (vs CA$0.023 loss in 2Q 2023) Aug 18 PharmaCielo Ltd. announced that it expects to receive CAD 2 million in funding Apr 11
PharmaCielo Ltd. announced that it expects to receive CAD 2 million in funding Apr 10
PharmaCielo Ltd., Annual General Meeting, Feb 20, 2024 Dec 28
Third quarter 2023 earnings released: CA$0.017 loss per share (vs CA$0.034 loss in 3Q 2022) Dec 01 PharmaCielo Ltd. announced that it has received CAD 4.78 million in funding Oct 07
Is PharmaCielo (CVE:PCLO) Using Too Much Debt? Oct 04
New major risk - Financial position Aug 31
Second quarter 2023 earnings released: CA$0.023 loss per share (vs CA$0.023 loss in 2Q 2022) Aug 31 Pharmacielo Ltd. Appoints Marc Lustig as CEO PharmaCielo Ltd. announced that it expects to receive CAD 5 million in funding
CEO, President & Chairman of the Board exercised options to buy CA$33k worth of stock. Jun 15
New minor risk - Share price stability Jun 08
First quarter 2023 earnings released: CA$0.023 loss per share (vs CA$0.019 loss in 1Q 2022) Jun 03
Full year 2022 earnings released: CA$0.096 loss per share (vs CA$0.18 loss in FY 2021) May 03
Is PharmaCielo (CVE:PCLO) Using Too Much Debt? Feb 25
Independent Lead Director recently bought CA$83k worth of stock Dec 02
Less than half of directors are independent Nov 16
Third quarter 2022 earnings released: CA$0.034 loss per share (vs CA$0.059 loss in 3Q 2021) Oct 29
Second quarter 2022 earnings released: CA$0.023 loss per share (vs CA$0.049 loss in 2Q 2021) Aug 30
PharmaCielo (CVE:PCLO) Is Making Moderate Use Of Debt Aug 03
Less than half of directors are independent Aug 01
PharmaCielo Ltd. Announces Board and Executive Changes Jul 29
CEO, President & Chairman of the Board recently bought CA$67k worth of stock Jul 17
PharmaCielo Ltd., Annual General Meeting, Sep 01, 2022 Jul 01
CEO, President & Chairman of the Board exercised options to buy CA$87k worth of stock. Jun 25
First quarter 2022 earnings: EPS and revenues miss analyst expectations Jun 01
High number of new directors May 31
Full year 2021 earnings: Revenues miss analyst expectations May 01
High number of new directors Apr 27
Independent Lead Director recently bought CA$92k worth of stock Mar 30
Independent Lead Director recently bought CA$292k worth of stock Mar 16
PharmaCielo Ltd. announced that it expects to receive CAD 15 million in funding Dec 23
Is PharmaCielo (CVE:PCLO) Weighed On By Its Debt Load? Dec 23
Third quarter 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 28
Independent Lead Director recently bought CA$1.8m worth of stock Sep 09
Director Marc Lustig has joined 5th company board Sep 02
Director Marc Lustig has joined 5th company board Sep 02
Director Marc Lustig has joined 5th company board Sep 02
Director Marc Lustig has joined 5th company board Sep 02
CEO, President & Director Henning von Koss has left the company Aug 24
Pharmacielo Ltd. Provides Revenue Guidance for the Second Half of 2021 Aug 22
Second quarter 2021 earnings released Aug 21
Independent Chairman of the Board Simon Langelier has left the company Jun 12
Chief Financial Officer Scott Laitinen has left the company Jun 04
First quarter 2021 earnings released: CA$0.047 loss per share (vs CA$0.064 loss in 1Q 2020) Jun 02
Is PharmaCielo (CVE:PCLO) A Risky Investment? May 14
Independent Director recently bought CA$115k worth of stock Apr 10
Third quarter 2020 earnings released: CA$0.083 loss per share (vs CA$0.04 loss in 3Q 2019) Apr 09
PharmaCielo Delivers First Commercial Shipment of THC-Free Broad-Spectrum Distillate Feb 19
Should PharmaCielo (CVE:PCLO) Be Disappointed With Their 9.8% Profit? Feb 16
New 90-day high: CA$2.68 Feb 11
PharmaCielo Provides Update on GMP Compliance Process Feb 03
PharmaCielo Ltd. Announces the Appointment of Caroline Lenardon for Expansion of Retail Investor Relations Capacity Dec 20
CEO, President & Director recently sold CA$88k worth of stock Dec 19
New 90-day high: CA$2.18 Dec 17
PharmaCielo Ltd., PharmaCielo Colombia Holdings S.A.S. Enter into Strategic Alliance with AssuredTrans Inc Dec 13
Revenue and earnings miss expectations Dec 02 Pharmacielo Ltd. Announces Step Down of David Attard as Board Member, Effective December 1, 2020
PharmaCielo Ltd. Delivers Its First Commercial Shipment of Medicinal Grade CBD Isolate Nov 19
New 90-day high: CA$0.74 Nov 19
PharmaCielo Ltd. Announces the First Harvest Cycle of Six High-THC Cultivars Nov 07
PharmaCielo Ltd. announced that it expects to receive CAD 5 million in funding Nov 04
PharmaCielo Ltd. Appoints Marc Lustig as Lead Director Nov 03
PharmaCielo Ltd. Expands Portfolio of Cannabis Extracts to Meet Global B2b Medical-Grade Market Demand Sep 22
New 90-day low: CA$0.54 Sep 18
New 90-day low - CA$0.55 Aug 06 Shareholder Returns PCLO CA Pharmaceuticals CA Market 7D -11.1% 5.0% -0.1% 1Y -55.6% -46.9% 17.9%
See full shareholder returns
Return vs Market: PCLO underperformed the Canadian Market which returned 18.4% over the past year.
Price Volatility Is PCLO's price volatile compared to industry and market? PCLO volatility PCLO Average Weekly Movement 17.9% Pharmaceuticals Industry Average Movement 13.4% Market Average Movement 8.6% 10% most volatile stocks in CA Market 18.5% 10% least volatile stocks in CA Market 3.0%
Stable Share Price: PCLO's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: PCLO's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company PharmaCielo Ltd., together with its subsidiary, engages in cultivating, processing, and supplying medicinal-grade cannabis extracts in Canada. Its products include medicinal-grade dried cannabis flower, cannabis oil extracts, tetrahydrocannabinol and cannabidiol medical cannabis, and other cannabis related products, as well as provides telemedicine software. The company also exports its products.
Show more PharmaCielo Ltd. Fundamentals Summary How do PharmaCielo's earnings and revenue compare to its market cap? PCLO fundamental statistics Market cap CA$14.43m Earnings (TTM ) -CA$14.03m Revenue (TTM ) CA$2.60m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) PCLO income statement (TTM ) Revenue CA$2.60m Cost of Revenue CA$2.57m Gross Profit CA$31.08k Other Expenses CA$14.06m Earnings -CA$14.03m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.083 Gross Margin 1.20% Net Profit Margin -540.35% Debt/Equity Ratio -275.0%
How did PCLO perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/07 01:06 End of Day Share Price 2025/02/07 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources PharmaCielo Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution null null Stifel Canada Robert Fagan Stifel Canada
